5 February 2024 - According to a Federal Government Medicare Payment Advisory Commission report published last month, more than 40% of Medicare beneficiaries still have no access through their insurance to Humira referenced biosimilars, despite several products having discounts of over 80% compared to the original Humira. 

When biosimilars are covered they’re usually on the same patient cost sharing tier as Humira, which doesn’t favour their uptake.

Read Forbes article